drugset / Trial / NCT07379398
Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
Major objectives to evaluate the efficacy and safety of lparomlimab and Tuvonralimab Injection ((QL1706, an Anti-PD-1/CTLA-4 Combined Antibody)) combined with SBRT in patients with early-stage non-small cell lung cancer.
Timeline
- Start
- 2026-04-01
- Primary completion
- 2029-06-30
- Completion
- 2031-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iparomlimab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Tuvonralimab | Monoclonal antibody | 5 mg/kg | — |